AG klinische und translationale Präzisionsonkologie
Every cancer is unique. Precision oncology aims at identifying personalized treatment options through molecular cancer profiling. In our group, we focus on creating reproducible and evidence-based individualized treatment options.
Sie befinden sich hier:
How patients can benefit through our research
For our ultimate goal to improve treatment strategies we directly translate molecular profiling technologies from routine panel sequencing and immunohistochemistry to multi-omics analyses into clinical care through the weekly Charité molecular tumor conference. Here we bring our latest results from analyzing clinical and molecular data and knowledge of the mechanisms of tumor biology to the table and discuss “real life cases” with a variety of experts.
Clinical precision oncology
Since every cancer is unique, reproducible and evidence-based decision-making is a challenge in precision oncology. We collaborate in several national and international working groups to streamline workflows, evidence levels and databases to help translate molecular profiles into personalized treatment using the best available data.
Clinical precision oncology - Selected Publications
- Zeitschrift (Journal):Front Oncol. Jahr:2023;
- Zeitschrift (Journal):Eur J Cancer Jahr:2023;
- Zeitschrift (Journal):Nucleic Acids Res. Jahr:2022;
Zeitschrift (Journal):BMC Med. Jahr:2022;
Titel:Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards
Translational precision oncology
The combined analysis of clinical and molecular data allows for an in-depth analysis of mechanisms underlying response and resistance to personalized therapies. We aim at harnessing these data to improve understanding of tumor biology and ultimately identify novel treatment strategies.
Translational precision oncology - Selected Publications